Press Releases

Company press releases and official corporate announcements.

A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.

Articles

24,022 total articles

Radiopharm Theranostics Receives Positive Recommendation from Data Safety and Monitoring Committee to Advance to Cohort 4 in 177Lu-RAD202 Phase 1 HEAT Clinical Trial

Radiopharm Theranostics Receives Positive Recommendation from Data Safety and Monitoring Committee to Advance to Cohort 4 in 177Lu-RAD202 Phase 1 HEAT Clinical Trial

Radiopharm Theranostics received a positive recommendation from the Data Safety and Monitoring Committee to advance its Phase 1 clinical trial of 177Lu-RAD202 to a higher dose level of 180mCi in patients with HER2-positive advanced solid tumors. This advancement follows encouraging safety and biodistribution results in earlier cohorts, marking prog…

Tilray Strengthens Global Medical Cannabis Leadership with Major Production Increase to Meet International Demand

Tilray Strengthens Global Medical Cannabis Leadership with Major Production Increase to Meet International Demand

Tilray Brands, Inc. has significantly expanded its global medical cannabis cultivation capacity from 210 to approximately 275 metric tonnes annually, enhancing supply from its Quebec and EU-GMP-certified Portugal facilities. This expansion strengthens Tilray's leadership in key international medical cannabis markets including Canada, Europe, Austra…

NovaBridge Reports First Half 2026 Financial Results and Highlights Pipeline Momentum and Strategic Execution

NovaBridge Reports First Half 2026 Financial Results and Highlights Pipeline Momentum and Strategic Execution

NovaBridge Biosciences reported its first half 2026 financial results showing increased R&D and administrative expenses reflecting advancement of its pipeline. The company announced key clinical milestones including plans to start a registrational Phase 3 study of givastomig by year-end 2026 under a potential FDA Accelerated Approval Pathway and pr…

UroGen Announces Strategic Collaboration and Investment Agreements with IntraGel to Access Biodegradable Sustained-Release Gel Platform and Expand Oncology Pipeline

UroGen Announces Strategic Collaboration and Investment Agreements with IntraGel to Access Biodegradable Sustained-Release Gel Platform and Expand Oncology Pipeline

UroGen Pharma Ltd. announced a strategic collaboration and equity investment in IntraGel Therapeutics to access its proprietary biodegradable sustained-release gel platform (SRGel). This agreement grants UroGen research licensing and exclusive options to develop up to three novel oncology products, along with an exclusive option to commercialize Tu…

ARRAY Technologies to Detail Balance-of-System Strategy and APA Long-Term Growth Opportunities at the APA Investor Technology Showcase Today

ARRAY Technologies to Detail Balance-of-System Strategy and APA Long-Term Growth Opportunities at the APA Investor Technology Showcase Today

ARRAY Technologies held its APA Investor Technology Showcase to detail its strategy to evolve from a tracker-only company into a fully integrated energy infrastructure platform, highlighting progress with APA Solar integration, growth opportunities, and the pending acquisition of Affordable Wire Management to expand into solar infrastructure compon…

Fractyl Health to Host Virtual Commercial Strategy Day on Tuesday, September 1, 2026: The Potential Path to Commercializing Revita®, a Procedural Therapy for Post-GLP-1 Weight Maintenance

Fractyl Health to Host Virtual Commercial Strategy Day on Tuesday, September 1, 2026: The Potential Path to Commercializing Revita®, a Procedural Therapy for Post-GLP-1 Weight Maintenance

Fractyl Health announced a virtual Commercial Strategy Day for September 1, 2026, to discuss the commercialization potential and go-to-market plan for Revita®, their procedural therapy designed to maintain weight loss after GLP-1 treatment cessation. This follows encouraging one-year data showing significant weight maintenance after a single Revita…

Aclarion Announces Addition of University of Arizona College of Medicine – Phoenix as CLARITY Trial Site

Aclarion Announces Addition of University of Arizona College of Medicine – Phoenix as CLARITY Trial Site

Aclarion, Inc. announces the University of Arizona College of Medicine – Phoenix as a new clinical site in its ongoing CLARITY trial, a pivotal multi-center study evaluating Nociscan's ability to identify painful spinal discs and improve outcomes in patients undergoing surgery for chronic low back pain. The addition of this prominent neurosurgery a…

Parsons Selected for $350M Seabed to Space ISR Effort

Parsons Selected for $350M Seabed to Space ISR Effort

Parsons Corporation secured a $350 million IDIQ contract from Naval Information Warfare Center Pacific to provide full lifecycle engineering and technical services for the Seabed to Space Intelligence Surveillance Reconnaissance program. This contract supports development, deployment, and sustainment of ISR systems across maritime, air, land, and s…

AIR Global Reports 2026 First-Half Results

AIR Global Reports 2026 First-Half Results

AIR Global PLC reported a 3.7% revenue increase to $206.9 million in the first half of 2026 despite supply chain disruptions from the Strait of Hormuz closure. Adjusted EBITDA remained stable at $71.7 million year-over-year. However, the company posted a net loss of $81.8 million largely due to one-time IPO-related expenses and costs associated wit…

SGLY Enters Into Non-Binding Strategic Framework Agreement for Potential 900-Acre South Carolina AI Data Center Campus

SGLY Enters Into Non-Binding Strategic Framework Agreement for Potential 900-Acre South Carolina AI Data Center Campus

SingularityNET (SGLY), a Nasdaq-listed digital infrastructure and high-performance computing company, has entered a non-binding strategic framework agreement with Florence Development LLC to evaluate the potential development of a 900-acre AI computing and data center campus in Florence, South Carolina. The site could initially support approximatel…

BioNTech Highlights Late-Stage Lung Cancer Pipeline Momentum and First Global Data for Pumitamig/Elfetabart Drozuntecan Novel-Novel Combination at WCLC 2026

BioNTech Highlights Late-Stage Lung Cancer Pipeline Momentum and First Global Data for Pumitamig/Elfetabart Drozuntecan Novel-Novel Combination at WCLC 2026

BioNTech presented new clinical data at the IASLC 2026 World Conference on Lung Cancer demonstrating progress across its lung cancer pipeline, including first global data for the novel pumitamig and elfetabart drozuntecan combination, updated survival results for gotistobart, and advancement in mRNA immunotherapies. The data reinforce BioNTech's le…